A5043889649- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Global Cancer Incidence and Screening
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
- Appendicitis Diagnosis and Management
- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- Intraperitoneal and Appendiceal Malignancies
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Surgical Treatments
- Cancer Cells and Metastasis
- Multiple and Secondary Primary Cancers
- Genetic factors in colorectal cancer
- Healthcare professionals’ stress and burnout
- Abdominal Trauma and Injuries
- Gallbladder and Bile Duct Disorders
- Organizational and Employee Performance
- Cancer Mechanisms and Therapy
Sylvester Comprehensive Cancer Center
2022-2025
University of Miami
2022-2025
The University of Texas Southwestern Medical Center
2017-2023
The University of Texas MD Anderson Cancer Center
2021-2022
Kaiser Permanente
2022
University of Pittsburgh Medical Center
2020
Southwestern Medical Center
2018
Southwestern University
2018
Dallas VA Medical Center
2018
Medical University of South Carolina
2018
Periampullary adenocarcinoma (PAC) is stratified anatomically: ampullary (AA), distal cholangiocarcinoma (DCC), duodenal (DA), and pancreatic ductal (PDAC). We aimed to determine differences in incidence, prognosis, treatment stage-matched PAC patients a longitudinal study.PAC were identified The National Cancer Database from 2004 2012. Clinicopathological variables compared between subtypes. Covariate-adjusted use OS compared.The 116 705 with identified: 1320 (9%) AA, 3732 (3%) DCC, 7142...
Fragmented cancer care (FC), or received from multiple institutions, increases systemic health costs and potentiates disparities. There is a paucity of data on mechanisms contributing to FC the resulting effect patient outcomes. This study characterized patient- hospital-level factors associated with FC, time treatment (TTT), overall survival (OS) in patients hepatocellular carcinoma (HCC).Patients newly diagnosed HCC 2004 2015 receiving were identified Texas Cancer Registry. Patient-...
Background: Despite an increasing burden of nonalcoholic steatohepatitis (NASH), limited data are available comparing outcomes NASH-related hepatocellular carcinoma (HCC) versus other etiologies. Methods: Patient demographic and tumor characteristics were collected for 1,051 patients diagnosed with NASH-, alcohol-related liver disease (ALD)–, hepatitis C virus (HCV)–, B (HBV)–related HCC at 2 large health systems from January 2008 through December 2016. demographics, clinical...
Background A paucity of data exists regarding the natural history and outcome measures adenosquamous carcinoma pancreas (ASCP), a histology distinct from pancreatic adenocarcinoma (PDAC). The aim this study is to characterize clinicopathological features ASCP in large cohort patients comparing surgically resected PDAC. Methods We identified diagnosed with or PDAC National Cancer Database 2004 2012. Patient demographics, tumor characteristics, treatment regimens, overall survival were...
701 Background: Treatment paradigms are shifting toward neoadjuvant therapy (NAT) for resectable (R) and borderline (BR) pancreatic cancer (PC) based on the rationale of treating occult metastatic disease, potentially downstaging patients (pts) to resectability if anatomically unresectable and, most importantly, selection biology pts likely benefit from morbid surgery. While benefits NAT PC have been well described, what remains underreported true attrition rates underlying reasons failure...